Bedaquiline and delamanid result in low rates of unfavourable outcomes among TB patients in Eswatini.

Since 2015, Eswatini has been scaling up bedaquiline (BDQ) and delamanid (DLM) based drug-resistant TB treatment regimens under programmatic conditions. Identification of factors associated with treatment outcomes in patients receiving BDQ and/or DLM either as a new treatment initiation or drug substitution. This is a retrospective cohort study of patients receiving BDQ and/or DLM in Eswatini between March 2015 and October 2018.